- Conditions
- Persistent Atrial Fibrillation
- Interventions
- AtriCure EPi-Sense-AF Guided Coagulation System with VisiTrax, Endocardial RF Catheter ablation using Open Irrigated-tip RF Abaltion Catheter with unidirectional or bidirectional steering
- Device
- Lead sponsor
- AtriCure, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Denver, Colorado + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 7,627
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Spinal Cord Injury, Stroke, Amputees
- Interventions
- Therapy Sessions
- Device
- Lead sponsor
- Brooks Rehabilitation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Tampa, Florida
- Conditions
- Episodic Migraine
- Interventions
- Atogepant, Placebo
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 910 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 138
- States / cities
- Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 112 more
- Conditions
- Myopia
- Interventions
- etafilcon A, galyfilcon A
- Device
- Lead sponsor
- Johnson & Johnson Vision Care, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 504 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 25
- States / cities
- Costa Mesa, California • Fresno, California • Louisville, Colorado + 22 more
- Conditions
- Musculoskeletal Pain
- Interventions
- Stretching
- Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Mankato, Minnesota + 3 more
- Conditions
- Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Interventions
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 90
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 78 more
- Conditions
- Residual Neuromuscular Blockade
- Interventions
- TetraGraph
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Breast Carcinoma
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Prostate Cancer
- Interventions
- bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,538 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 499
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 353 more
- Conditions
- Maternity, Pregnancy, Labor and Delivery, Hemodynamic Changes
- Interventions
- ClearSight™ System, Transthoracic Echocardiography, Passive Leg Raising (PLR) Maneuver
- Device · Procedure
- Lead sponsor
- Ayse Zeynep Turan Civraz
- Government
- Eligibility
- 18 Years to 45 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- ADHD
- Interventions
- Placebo, PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg, PRC-063 100 mg
- Drug
- Lead sponsor
- Rhodes Pharmaceuticals, L.P.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 33
- States / cities
- Los Angeles, California • National City, California • Newport Beach, California + 27 more
- Conditions
- Carcinoma, Non-small-cell Lung, Metastases, Neoplasm
- Interventions
- ZD1839 (Gefitinib)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 626
- States / cities
- Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 623 more
- Conditions
- Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant, Gastrointestinal Stromal Cell Tumors
- Interventions
- ziftomenib, imatinib mesylate
- Drug
- Lead sponsor
- Kura Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 26 more
- Conditions
- Overweight, Type 2 Diabetes, Obesity
- Interventions
- Petrelintide, Placebo
- Drug · Other
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 48
- States / cities
- Cullman, Alabama • Chandler, Arizona • Phoenix, Arizona + 43 more
- Conditions
- Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
- Interventions
- TX000045- Dose A, TX000045- Dose B, Placebo
- Drug
- Lead sponsor
- Tectonic Therapeutic
- Industry
- Eligibility
- 18 Years to 83 Years
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • San Francisco, California + 21 more
- Conditions
- Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer), Non Clear Cell Renal Cell Carcinoma (nccRCC)
- Interventions
- Darlifarnib, Cabozantinib, Adagrasib
- Drug
- Lead sponsor
- Kura Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 17 more
- Conditions
- Stage III Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage IVA Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma, Stage IIC Adult Soft Tissue Sarcoma
- Interventions
- doxorubicin, filgrastim, ifosfamide, biological response modifier therapy, brachytherapy, chemotherapy, colony-stimulating factor therapy, conventional surgery, cytokine therapy, intraoperative radiotherapy, radiation therapy, surgery
- Drug · Procedure
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 216
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Tezepelumab, Placebo
- Biological · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more
- Conditions
- Asthma
- Interventions
- Placebo, FP 100mcg, FP 250mcg, FP 500mcg, FSC 100/50mcg, FSC 250/50mcg, FSC500/50mcg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Jasper, Alabama • Glendale, Arizona + 43 more
- Conditions
- Chronic Low Back Pain
- Interventions
- ORAVESCENT Fentanyl Citrate
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 17
- States / cities
- Jonesboro, Arkansas • Bakersfield, California • San Diego, California + 13 more
- Conditions
- Extrapulmonary Neuroendocrine Cancer (epNEC)
- Interventions
- Obrixtamig, Carboplatin, Etoposide, Ventana DLL3 RxDx assay
- Drug · Device
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • Duarte, California • San Francisco, California + 17 more
- Conditions
- Hyperthyroidism; Goiter, Multinodular Goiter, Thyroid Nodules, Thyroid Disease, Hyperthyroidism, Toxic Multinodular Goiter
- Interventions
- Data Collection
- Other
- Lead sponsor
- Sarasota Memorial Health Care System
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Sarasota, Florida • Atlanta, Georgia + 1 more
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage IVB Cervical Cancer
- Interventions
- Bevacizumab, Cisplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration, Topotecan Hydrochloride
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 541
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 351 more
- Conditions
- HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma
- Interventions
- TG4001, Avelumab
- Biological · Drug
- Lead sponsor
- Transgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota